Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.

In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.

A method for treating cancer in a patient who is resistant to a protein kinase inhibitor, administering an anticancer agent containing, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof is disclosed. Here, the patient may carry active RON. In addition, the patient may carry normal KRAS gene. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.

A method for treating cancer in a patient who is resistant to a protein kinase inhibitor, administering an anticancer agent containing, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof is disclosed. Here, the patient may carry active RON. In addition, the patient may carry normal KRAS gene. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.

Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies.

Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies.

Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies.

A method for the treatment or prevention of a cardiovascular event in a subject with atherosclerotic vascular disease comprising the step of: b) administering a therapeutically effective amount of a compound of formula (I), a known colchicine derivative and/or a salt thereof ##STR00001##
wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 independently represent hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.3-6 cycloalkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.2-4 acylamino, C.sub.1-4 alkyl or dialkylamino, hydroxyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, a group of the formula —SO.sub.2N(R.sup.x).sub.2 or SO.sub.2R.sup.x where R.sup.x is C.sub.1-4 alkyl, C.sub.1-4 acyloxy, or optionally substituted phenyl, optionally substituted phenoxy; R.sub.7 and R.sub.8 independently represent hydrogen, C.sub.1-4 alkyl or C.sub.1-4 acyl; and R.sub.5′, R.sub.5″, R.sub.6′ and R.sub.6″ independently represent hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.3-6 cycloalkyl, halogen, C.sub.1-4 haloalkyl, nitro, amino, C.sub.2-4 acylamino, hydroxyl, C.sub.1-4 alkoxy or C.sub.1-4 alkylthio a group of the formula —SO.sub.2N(R.sup.x).sub.2 or SO.sub.2R.sup.x where R.sup.x is C.sub.1-4 alkyl, C.sub.1-4 acyloxy, or optionally substituted phenyl.